Nabriva Therapeutics PLC (NASDAQ:NBRV)
| 2.10 Delayed Data As of 4:00pm ET |  -0.07 / -3.23%Today’s Change | 2.04 Today|||52-Week Range 21.86 | -85.97% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $6.5M |
Company Description
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Contact Information
Nabriva Therapeutics Plc 25-28 North Wall Quay Dublin Dublin 1 |
Employees
Shareholders
| Other institutional | 1.03% |
| Individual stakeholders | 1.01% |
| Mutual fund holders | 0.79% |
Top Executives
| Theodore R. Schroeder | Chief Executive Officer & Director |
| Steven P. Gelone | President, Chief Operating Officer & Director |
| Dan Dolan | Chief Financial Officer |
| Christine Guico-Pabia | Chief Medical Officer |
| Jodi VanDerveer | Senior Vice President & Head-Human Resources |
